Healthcare

HJ 35 is a joint resolution from the Montana Legislature urging federal officials to modify current federal land management and wildfire policies. It calls for an aggressive initial attack on wildfires across all federal lands and for federal forest roads to remain open for access and fire suppression. The resolution also recommends that EPA air quality standards include wildfire smoke and that federal "let it burn" policies be reversed, ensuring NEPA processes are followed. Finally, it advocates for increased involvement of state and local governments and stakeholder groups in federal fire management decisions to protect Montana's communities.

HB 476 establishes a grant program to fund the installation and maintenance of newborn safety devices. The Department of Public Health and Human Services will award competitive grants, up to $20,000 per applicant, to eligible fire departments, hospitals, and law enforcement agencies. The department is also responsible for creating rules for the application process and evaluation criteria. The bill appropriates $160,000 from the general fund for this program, which is effective July 1, 2025, and terminates on June 30, 2027.

Senate Bill 495 eliminates the Tobacco Prevention Advisory Board. The bill repeals the specific section of law that established this board. It also amends existing statute to remove the board from the list of entities funded by state special revenue accounts, which are primarily used for tobacco disease prevention programs and the Children's Health Insurance Program. The direct effect is the dissolution of the advisory board, which previously provided guidance for these programs.

HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.